Dodge v. Mereo Biopharma Group PLC (1:26-cv-988) was filed Feb. 4, 2026 in the Southern District of New York. The lead plaintiff filed an amended complaint on July 13, 2026.
Mereo BioPharma's American Depositary Shares failed to hold a $1.00 minimum bid price for 30 consecutive business days, and Nasdaq gave the company until August 17, 2026 to regain compliance. The company's 2024 annual report shows a net loss of $43.3 million and $69.8 million of cash.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $30.1 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Mereo BioPharma Group
Is there a class action against Mereo BioPharma Group?
Our latest story on this, dated Aug 19, 2026: "Mereo BioPharma faces securities class action naming its CEO and chief scientific officer". The story links the filing or release it is based on. Read the story.
Has Mereo BioPharma Group raised money recently?
Our latest story on this, dated Nov 12, 2024: "Mereo BioPharma reports $80.5 million cash, says it funds operations into 2027". The story links the filing or release it is based on. Read the story.
Has Mereo BioPharma Group received a Nasdaq deficiency notice?
Our latest story on this, dated Feb 17, 2026: "Mereo BioPharma gets Nasdaq minimum bid price deficiency notice on its ADSs". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Mereo BioPharma Group?
Mereo BioPharma Group plc trades under the ticker MREO on NASDAQ.
Where is Mereo BioPharma Group listed?
Mereo BioPharma Group plc is listed on NASDAQ. Our directory also records these other listings: LSE:0A9G.
What is the SEC CIK of Mereo BioPharma Group?
The SEC Central Index Key (CIK) for Mereo BioPharma Group plc is 1719714. Its filings are on SEC EDGAR.
How many shares does Mereo BioPharma Group have outstanding?
798,454,864 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is Mereo BioPharma Group listed under?
Our directory records Mereo BioPharma Group plc under United Kingdom.
What does Mereo BioPharma Group do?
Our directory classifies Mereo BioPharma Group plc as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Mereo BioPharma Group?
The ISIN recorded for Mereo BioPharma Group plc is US5894921072.
Does aibio.space cover Mereo BioPharma Group?
aibio.space lists Mereo BioPharma Group plc among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Mereo BioPharma Group incorporated?
SEC records list its state or country of incorporation as X0.
What was Mereo BioPharma Group's revenue last year?
$500,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Mereo BioPharma Group profitable?
Mereo BioPharma Group plc reported a net loss of $41.9 million for the fiscal year ended Dec 31, 2025, and used $31.0 million of cash in operations, per its annual report to the SEC.
How much does Mereo BioPharma Group spend on research and development?
$17.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: Mereo BioPharma Group
Members talk about Mereo BioPharma Group (MREO). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Mereo BioPharma Group, newest first. Each line links the filing it comes from.
Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source
Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 1.01,2.02,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:MREO on TradingView.
SEC filings and registration
SEC name
Mereo BioPharma Group plc
CIK
1719714
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
MREO (Nasdaq)
State or country of incorporation
X0
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
ONE CAVENDISH PLACE, LONDON, W1G 0QF
Phone
4403330237300
Shares outstanding
798,454,864 as of 2026-08-07 (10-Q filed 2026-08-11)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Mereo BioPharma Group plc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MREO, recorded under United Kingdom. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio